Amyotrophic Lateral Sclerosis (ALS)

Some preclinical evidence suggests that the endocannabinoid system may play a critical role in the development of ALS. In 2006, for example, one study found that compounds that connected with a specific cannabinoid receptor (CB2) delayed ALS symptoms in mouse models. In a review published in the American Journal of Hospice and Palliative Care, authors cited preclinical data suggesting that cannabis has anti-inflammatory, antioxidant, and neuroprotective effects. They also suggest that it may have beneficial effects in key pharmaceutical targets in ALS, including:

(Source: Carter GT, Abood ME, Aggarwal SK, Weiss MD., “Cannabis and amyotrophic lateral sclerosis: hypothetical and practical applications, and a call for clinical trials.” Am J Hosp Palliat Care. 2010 Aug;27(5):347-56. doi: 10.1177/1049909110369531. Epub 2010 May 3)

Read More